TPST Tempest Therapeutics Inc

Price (delayed)

$1.29

Market cap

$19.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.01

Enterprise value

$25.15M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct ...

Highlights
The EPS has soared by 67% YoY and by 5% from the previous quarter
Tempest Therapeutics's debt has decreased by 40% YoY and by 3.5% from the previous quarter
The net income has plunged by 64% from the previous quarter but it has grown by 3.8% YoY
The equity has plunged by 93% YoY and by 88% from the previous quarter
The quick ratio has dropped by 76% since the previous quarter and by 66% year-on-year

Key stats

What are the main financial stats of TPST

TPST stock price

How has the Tempest Therapeutics stock price performed over time
Intraday
1.57%
1 week
-25.43%
1 month
-38.86%
1 year
-81.29%
YTD
-55.05%
QTD
-21.34%

Financial performance

How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43.36M
Net income
-$43.1M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 64% from the previous quarter but it has grown by 3.8% YoY
The company's operating income has shrunk by 63% QoQ but it rose by 3.6% YoY

Price vs fundamentals

How does TPST's price correlate with its fundamentals

Growth

What is Tempest Therapeutics's growth rate over time

Valuation

What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
22.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 67% YoY and by 5% from the previous quarter
The price to book (P/B) is 119% higher than the last 4 quarters average of 10.1
The equity has plunged by 93% YoY and by 88% from the previous quarter

Efficiency

How efficient is Tempest Therapeutics business performance
The ROE has plunged by 139% YoY and by 136% from the previous quarter
The company's return on assets has shrunk by 115% QoQ and by 108% YoY
TPST's return on invested capital has dropped by 56% since the previous quarter

Dividends

What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TPST.

Financial health

How did Tempest Therapeutics financials performed over time
The company's total assets is 8% higher than its total liabilities
The quick ratio has dropped by 76% since the previous quarter and by 66% year-on-year
The current ratio has dropped by 70% since the previous quarter and by 56% year-on-year
The equity has plunged by 93% YoY and by 88% from the previous quarter
Tempest Therapeutics's debt has decreased by 40% YoY and by 3.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.